Anti-obesity Agents: A Focused Review on the Structural Classification of Therapeutic Entities

Sangmi Oh; Koon Soon Kim; Young Sun Chung; Minho Shong; Seung Bum Park
April 2009
Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p466
Academic Journal
In addition to its enormous impacts on an individual's quality of life, obesity is a daunting health problem in the world today and the increasing rate of obesity is now causing a severe burden on health care systems. Fortunately, the normalization or reduction of increased body fat reverses the obesity-associated morbidities, such as hypertension, glucose intolerance, dyslipidemia, and fatty liver diseases. However, the modification of lifestyle in a case of established clinical obesity is very difficult to achieve. Recent breakthroughs in relation to the molecular mechanism regulating body weight and energy metabolism give us hopes for the development of anti-obesity drugs. Even with the high social demand for an effective treatment for obesity and extensive researches, both in academia and the pharmaceutical industry, only two weight-loss drugs, sibutramine and orlistat, have been approved by the FDA for long-term treatment. In addition, the current bottleneck in drug discovery shows that a more detailed understanding of the pathogenesis of obesity is an essential element for the development of efficacious treatment. In this review article, we focus on the structural origin of chemical entities for anti-obesity treatment along with the rationale for drug discovery, rather than categorizing the clinical efficacy or pharmacological target of obesity. For the clarification of the structural origin, we formed a collection with 4 major groups, including natural products, natural product mimetics, synthetic small molecules, and peptides/hormones. This analysis might provide strategic plans for medicinal chemists, biologists, and physicians to begin an optimistic era with a new class of pharmaceutical adjuncts for obesity therapy.


Related Articles

  • The uphill battle facing antiobesity drugs. Daubresse, M; Alexander, G C // International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377 

    The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...

  • FDA Approves Lorcaserin for Treatment of Obesity.  // International Cardiovascular Research Journal;2012, Vol. 6 Issue 2, p66 

    The article reports on the approval of lorcaserin by the U.S. Food and Drug Administration (FDA) for the treatment of obesity as of June 2012.

  • Alli drug debuts: ally or foe? Lofshult, Diane // IDEA Fitness Journal;Sep2007, Vol. 4 Issue 8, p79 

    The article reports on the release of the first over-the-counter (OTC) weight loss drug to be approved by the U.S. Food and Drug Administration (FDA) called Alli. The drug is a new version of the existing drug orlistat manufactured by GlaxoSmithKline. It works in the digestive tract to prevent...

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • New drug policy in childhood obesity. Molnár, D.; Molnár, D // International Journal of Obesity;Sep2005 Supplement 2, Vol. 29, pS62 

    Objective: To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.Methods: The paper reviews current and investigational antiobesity drugs.Results: At present, there are only...

  • Lorcaserin: A novel, selective 5-HT2C-receptor agonist for the treatment of obesity. Pauli, Maribeth // Formulary;Jun2010, Vol. 45 Issue 6, p180 

    The article discusses research into the use of the drug lorcaserin for the treatment of obesity. Pharmacologic treatments for obesity are meant to supplement other treatments including lifestyle modification and behavioral therapy. Lorcaserin is a selective 5-HT2C-receptor agonist which has been...

  • Abraham Thomas.  // Nature Reviews Drug Discovery;Feb2011, Vol. 10 Issue 2, p90 

    An interview with Abraham Thomas, head of the Endocrinology, Diabetes, Bone and Mineral Disorders division at Henry Ford Hospital in Detroit, Michigan, is presented. When asked on the lessons that companies should take from the panel meetings on potential anti-obesity agents, he refers to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics